ARCHIVES

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

Waksal To Pay Back $800,000 In Profits From Stock Sales

March 14, 2003

Young Elected ACS President, Von eschenback Pres.-Elect.

November 9, 2001

FDA, NCI, CMS Announce Biomarker Initiative; First Project To Validate FDG-PET As Predictor Of Tumor Response In Non-Hodgkin’s Lymphoma.

February 17, 2006

Book By Clinical Researcher Makes Case For Nationwide Reforms

July 30, 1993

NSABP Objects to “Closed Process” For Review Of P-4 Breast Cancer Chemoprevention Trial.

April 20, 2007

Funding opportunities listed.

October 29, 2004